Vaxzevria, cjepivo protiv COVID-19 (ChAdOx1-S[rekombinantni])
The medicinal product has been authorised by the European Commission (EC) via centralised procedure in all EU Member States, based on the European Medicines Agency (EMA) experts' opinion.
| Name | Vaxzevria, cjepivo protiv COVID-19 (ChAdOx1-S[rekombinantni]) |
|---|---|
| Former Name | COVID-19 Vaccine AstraZeneca |
| Active Substance | adenovirus čimpanze koji kodira glikoprotein šiljka virusa SARS-CoV-2 (ChAdOx1-S) |
| Prescription | na recept |
| Type of prescription | neponovljivi recept |
| Distribution | u ljekarni |
| ATC Code | J07BN02 |
| Medicinal product marketed in the Croatia | Privremeni prekid opskrbe |
| Summary of product characteristics (SmPC), labelling and package leaflet (PL) | download |
| Link to the European Medicines Agency's (EMA) product information | download |
| Link to the European Commission's (EC) decisions | download |
Direct Healthcare Professional Communication
| Name | Date | Download |
|---|---|---|
| Pismo zdravstvenim radnicima o riziku od trombocitopenije (uključujući imunosnu trombocitopeniju) sa ili bez krvarenja kod primjene cjepiva Vaxzevria (ranijeg naziva COVID-19 Vaccine AstraZeneca) | 13.10.2021 | AstraZeneca AB |
| Pismo zdravstvenim radnicima o kontraindikaciji primjene cjepiva Vaxzevria (ranijeg naziva COVID-19 Vaccine AstraZeneca) u osoba koje su prethodno imale sindrom kapilarnog curenja | 23.06.2021 | AstraZeneca AB |
| Pismo zdravstvenim radnicima o povezanosti primjene cjepiva Vaxzevria (ranijeg naziva COVID-19 Vaccine AstraZeneca) i pojave tromboze u kombinaciji s trombocitopenijom - 2.6.2021. | 02.06.2021 | AstraZeneca AB |
| Pismo zdravstvenim radnicima o povezanosti primjene cjepiva Vaxzevria (ranijeg naziva COVID-19 Vaccine AstraZeneca) i pojave tromboze u kombinaciji s trombocitopenijom | 14.04.2021 | AstraZeneca AB |
| Pismo zdravstvenim radnicima o riziku od trombocitopenije i poremećaja zgrušavanja krvi za cjepivo Vaxzevria (COVID-19 Vaccine AstraZeneca) | 24.03.2021 | AstraZeneca AB |
